Table 3.
Univariate and multivariate analyses of prognostic factors for disease‐free survival
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| P value | HR | 95% CI | P value | HR | 95% CI | |
| Age, y (≤70/>70) | .806 | 1.033 | 0.795‐1.339 | |||
| Gender (male/female) | .231 | 1.212 | 0.887‐1.689 | |||
| BMI, kg/m2 (≤22/>22) | .174 | 0.833 | 0.641‐1.085 | |||
| HBV (N/Y) | .723 | 1.065 | 0.756‐1.546 | |||
| HCV (N/Y) | .242 | 1.168 | 0.901‐1.521 | |||
| CRP, mg/dL (≤0.20/>0.20) | <.001 | 2.048 | 1.529‐2.715 | .905 | 1.033 | 0.603‐1.774 |
| Alb, g/dL (≥3.5/<3.5) | <.001 | 2.361 | 1.691‐3.235 | .324 | 0.637 | 0.244‐1.544 |
| AST, IU/L (≤35/>35) | .002 | 1.515 | 1.166‐1.966 | .341 | 1.162 | 0.852‐1.583 |
| ALT, IU/L (≤34/>34) | .129 | 1.229 | 0.941‐1.599 | |||
| Plt, ×104/mm3 (≥14/<14) | .046 | 1.302 | 1.003‐1.694 | .022 | 1.471 | 1.056‐2.058 |
| PT, % (≥80/<80) | .499 | 1.108 | 0.817‐1.483 | |||
| T. Bil, mg/dL (≤1/>1) | .747 | 1.059 | 0.736‐1.482 | |||
| ICGR15, % (≤15/>15) | <.001 | 1.684 | 1.296‐2.191 | .027 | 1.501 | 1.046‐2.144 |
| AFP, ng/mL (≤10/>10) | .003 | 1.472 | 1.132‐1.916 | .058 | 1.335 | 0.989‐1.805 |
| DCP, mAU/mL (≤100/>100) | .052 | 1.302 | 0.997‐1.696 | |||
| Child‐Pugh (A/B) | .018 | 1.748 | 1.104‐2.632 | .853 | 0.947 | 0.525‐1.653 |
| Liver damage (A/B, C) | <.001 | 1.647 | 1.239‐2.171 | .208 | 0.771 | 0.509‐1.155 |
| Tumor number (1/>1) | <.001 | 2.228 | 1.713‐2.893 | <.001 | 1.766 | 1.271‐2.441 |
| Tumor size, mm (≤50/>50) | <.001 | 1.774 | 1.297‐2.389 | .477 | 1.166 | 0.757‐1.763 |
| Anatomical resection (Y/N) | .092 | 1.268 | 0.961‐1.661 | |||
| Operation time, min (≤300/>300) | .116 | 1.233 | 0.949‐1.608 | |||
| Blood loss, mL (≤1000/>1000) | .241 | 1.306 | 0.825‐1.966 | |||
| LC (N/Y) | .011 | 1.457 | 1.091‐1.929 | .249 | 1.222 | 0.867‐1.714 |
| MVI (N/Y) | <.001 | 2.101 | 1.555‐2.802 | .002 | 1.797 | 1.231‐2.591 |
| Histological grade | ||||||
| Well, moderately differentiated/poorly differentiated | .282 | 1.264 | 0.832‐2.023 | |||
| IM (N/Y) | <.001 | 2.235 | 1.537‐3.159 | .264 | 1.323 | 0.804‐2.128 |
| PNI (≥40/<40) | <.001 | 2.211 | 1.682‐2.888 | .089 | 0.705 | 0.477‐1.056 |
| CAR (≤0.027/>0.027) | <.001 | 2.181 | 1.671‐2.841 | .012 | 1.813 | 1.145‐2.789 |
| GPS (0/1, 2) | <.001 | 3.173 | 2.361‐4.229 | .031 | 2.791 | 1.102‐7.597 |
| NLR (≤2.2/>2.2) | .046 | 1.296 | 1.003‐1.684 | .525 | 1.126 | 0.777‐1.617 |
| LMR (≥3.3/<3.3) | .011 | 1.473 | 1.097‐1.954 | .342 | 1.213 | 0.811‐1.796 |
| PLR (≤106/>106) | .257 | 1.163 | 0.894‐1.508 | |||
| PI (0/1, 2) | <.001 | 2.647 | 1.799‐3.778 | .208 | 0.572 | 0.221‐1.347 |
AFP, alpha‐fetoprotein; Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CAR, C‐reactive protein to albumin ratio; CRP, C‐reactive protein; DCP, des‐gamma‐carboxyprothrombin; GPS, Glasgow prognostic score; HBV, hepatitis B virus; HCV, hepatitis C virus; ICGR15, indocyanine green retention rate at 15 min; IM, intrahepatic metastasis; LC, liver cirrhosis; LMR, lymphocyte to monocyte ratio; MVI, microvascular invasion; NLR, neutrophil to lymphocyte ratio; PI, prognostic index; PLR, platelet to lymphocyte ratio; Plt, platelet count; PNI, prognostic nutritional index; PT, prothrombin time; T. Bil, total bilirubin.